Synthetic Biologics Inc (SYN) 2.30 $SYN
Synthetic Biologics Reports Year End 2013 Financial Results and Operational Update
PR Newswire - Mon Mar 31, 6:00AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, today reported financial results for the year ended December 31, 2013 and provided operational highlights.
Synthetic Biologics to Report Year End 2013 Financial Results
PR Newswire - Tue Mar 25, 10:17AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that it intends to release its financial results for the year ended December 31, 2013 on Monday, March 31, 2014.
Synthetic Biologics Inc. (SYN) in Focus: Stock up 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:04AM CDT
Synthetic Biologics Inc. was a big mover last session, as the company saw its shares rise over 9% on the day
Top Gainers Technical Data -- Research on First Solar, Oncothyreon, Unilife, and Synthetic Biologics
PR Newswire - Thu Mar 20, 7:07AM CDT
The US markets saw a negative sentiment on Wednesday, March 19, 2014, with the NASDAQ Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average ending the session at 16,222.17, down 0.70% and the S&P 500 edging 0.61% lower to finish the trading session at 1,860.77. The losses were broad based as all the ten sectors ended the session in negative. A number of stocks saw large movements, including First Solar Inc. (NASDAQ: FSLR), Oncothyreon Inc. (NASDAQ: ONTY), Unilife Corp. (NASDAQ: UNIS), and Synthetic Biologics Inc. (AMEX: SYN). Free technical research on FSLR, ONTY, UNIS, and SYN can be downloaded upon signing up at:
4 Stocks Under $10 to Trade for Breakouts
at The Street - Tue Mar 18, 8:41PM CDT
These under-$10 stocks are within range of triggering breakout trades.
Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta(TM), for Multiple Sclerosis
PR Newswire - Mon Mar 10, 6:00AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). The patent includes claims to the use of the Company's drug candidate, Trimesta(TM) (oral estriol), in conjunction with a gestagen for the treatment of multiple sclerosis (MS) and other autoimmune diseases. The patent also includes a claim for the administration of Trimesta(TM), a gestagen and a third standard of care MS agent, such as glatiramer acetate injection (Copaxone®), interferon beta-1a (Avonex®, Rebif®), interferon beta-1b (Betaseron®, Extavia®) or sphingosine-1-phosphate receptor modulator (Gilenya®). Through its wholly owned subsidiary, Synthetic Biologics holds the exclusive license to the newly issued U.S. Patent 8,658,627, as well as U.S. Patents 8,372,826 and 6,936,599 and pending patents for MS and other autoimmune diseases covering the uses of its oral estriol candidate, Trimesta(TM).
Synthetic Biologics to Present at the 26th Annual ROTH Conference
PR Newswire - Wed Mar 05, 6:00AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 26th Annual ROTH Conference being held on March 9-12, 2014 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Tuesday, March 11, 2014 at 2:00 p.m. (Pacific Time).
Board member of Synthetic Biologics, Steve H Kanzer, resigns
M2 - Thu Feb 27, 5:27AM CST
US-based biotechnology company Synthetic Biologics Inc (NYSE MKT:SYN) reported on Wednesday the resignation of its founder & board member, Steve H Kanzer.
Synthetic Biologics' Board of Directors Accepts Resignation of Long-Standing Founder and Board Member
PR Newswire - Wed Feb 26, 4:01PM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that Founder, Board member and subsidiary CEO and President, Steve H. Kanzer, has resigned from the Company, effective immediately, to return his focus to his venture capital and investment banking firms on a full-time basis.
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Synthetic Biologics (SYN) Worth Watching: Stock Soars 19.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:46AM CST
Synthetic Biologics was a big mover last session, with shares surging nearly 20%.
Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity
PR Newswire - Thu Feb 13, 2:57PM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that in view of the unusual market activity in the Company's stock, the NYSE MKT (the "Exchange") has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity.
Synthetic Biologics Announces Rhonda Voskuhl, M.D., to Present Trimesta(TM) Phase II Multiple Sclerosis Clinical Trial Results at the 2014 AAN Annual Meeting
PR Newswire - Mon Feb 10, 6:00AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating the Company's oral estriol product candidate, Trimesta(TM), for the treatment of relapsing-remitting multiple sclerosis (MS), will present topline results at the American Academy of Neurology's (AAN) 66th Annual Meeting in Philadelphia. The abstract titled, A Combination Trial of Estriol Plus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis, will be presented as part of the AAN Emerging Science program during two sessions, as follows:
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Synthetic Biologics to Present at the 2014 BIO CEO & Investor Conference
PR Newswire - Tue Feb 04, 6:00AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 10, 2014, at 10:00 a.m. (ET) at the Waldorf Astoria (Duke of Windsor room) in New York.
Intrexon: Living Better Through Synthetic Biology?
at Investor's Business Daily - Tue Jan 28, 1:03PM CST
Analysts have dropped their profit estimates for synthetic biotechnology firm Intrexon, and investors seem to be taking it in stride. Intrexon (XON) stock has soared this year, mainly on investor hopes of better results to come later from royalties...
Synthetic Biologics (SYN) Slumps: Stock Tanks 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:38AM CST
Synthetic Biologics shares fell by over 11%. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future.
Synthetic Biologics Strengthens Clinical & Regulatory Team to Support Expanding Pipeline of Infectious Disease Programs
PR Newswire - Mon Jan 27, 6:00AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Joseph Sliman, M.D., M.P.H., joined the team and will assume the role of Senior Vice President, Clinical & Regulatory Affairs, previously held by Carol Reed, M.D. In this position, Dr. Sliman will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the Company's regulatory initiatives. Dr. Sliman has more than 18 years of experience in clinical and public health research, including 10 years directing clinical projects and product development, in therapeutic areas such as infectious diseases and vaccines. Synthetic Biologics also announced that Dr. Reed will continue to contribute to the Company's team as a key clinical & regulatory advisor.
Synthetic Biology - Global Strategic Business Report - 2013: Profiles Players such as Sapphire Energy, Inc., Gingko Bioworks Inc and
M2 - Thu Jan 09, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/mvqmvm/synthetic_biology#summary) has announced the addition of the "Synthetic Biology - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Synthetic Biology in US$ Thousands by the following Application Areas: - Energy & Chemicals - Biotechnology & Pharmaceuticals - Others The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 38 companies including many key and niche players such as: -454 Life Sciences (US) -Agilent Technologies Inc. (US) -ATG Biosynthetics GmbH (Germany) -BP PLC. (UK) -Chromatin Inc. (US) -DNA2.0 (US) -E. I. du Pont de Nemours and Company (US) -Epoch Life Science, Inc. (US -Evolva SA (Switzerland) -Gen9 Inc (US) -GenScript USA, Inc. (US) -Gevo, Inc. (US) -Gingko Bioworks Inc (US) -Intrexon Corporation (US) -Joule Unlimited, Inc. (US) -LC Sciences LLC (US) -Life Technologies Corp. (US) -LS9, Inc. (US) -Metabolix (US) -MorphoSys AG (Germany) -OPXBIO Inc. -OriGene Technologies, Inc. -Sangamo BioSciences, Inc. (US) -Sapphire Energy, Inc. (US) -Solazyme, Inc. (US) -Synthetic Biologics, Inc. (US) -Synthetic Genomics, Inc. (US) -Verdezyne, Inc. For more information visit http://www.researchandmarkets.com/research/mv...gy#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Synthetic Biologics to Present at the Biotech Showcase(TM) 2014 Conference
PR Newswire - Wed Jan 08, 1:06PM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the Biotech Showcase(TM) 2014 conference next week in San Francisco, as follows:
Synthetic Biologics Reports Year End 2013 Financial Results and Operational Update
PR Newswire - Mon Mar 31, 6:00AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, today reported financial results for the year ended December 31, 2013 and provided operational highlights.
Synthetic Biologics to Report Year End 2013 Financial Results
PR Newswire - Tue Mar 25, 10:17AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that it intends to release its financial results for the year ended December 31, 2013 on Monday, March 31, 2014.
Synthetic Biologics Inc. (SYN) in Focus: Stock up 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 8:04AM CDT
Synthetic Biologics Inc. was a big mover last session, as the company saw its shares rise over 9% on the day
Top Gainers Technical Data -- Research on First Solar, Oncothyreon, Unilife, and Synthetic Biologics
PR Newswire - Thu Mar 20, 7:07AM CDT
The US markets saw a negative sentiment on Wednesday, March 19, 2014, with the NASDAQ Composite closing at 4,307.60, down 0.59%, the Dow Jones Industrial Average ending the session at 16,222.17, down 0.70% and the S&P 500 edging 0.61% lower to finish the trading session at 1,860.77. The losses were broad based as all the ten sectors ended the session in negative. A number of stocks saw large movements, including First Solar Inc. (NASDAQ: FSLR), Oncothyreon Inc. (NASDAQ: ONTY), Unilife Corp. (NASDAQ: UNIS), and Synthetic Biologics Inc. (AMEX: SYN). Free technical research on FSLR, ONTY, UNIS, and SYN can be downloaded upon signing up at:
4 Stocks Under $10 to Trade for Breakouts
at The Street - Tue Mar 18, 8:41PM CDT
These under-$10 stocks are within range of triggering breakout trades.
Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta(TM), for Multiple Sclerosis
PR Newswire - Mon Mar 10, 6:00AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). The patent includes claims to the use of the Company's drug candidate, Trimesta(TM) (oral estriol), in conjunction with a gestagen for the treatment of multiple sclerosis (MS) and other autoimmune diseases. The patent also includes a claim for the administration of Trimesta(TM), a gestagen and a third standard of care MS agent, such as glatiramer acetate injection (Copaxone®), interferon beta-1a (Avonex®, Rebif®), interferon beta-1b (Betaseron®, Extavia®) or sphingosine-1-phosphate receptor modulator (Gilenya®). Through its wholly owned subsidiary, Synthetic Biologics holds the exclusive license to the newly issued U.S. Patent 8,658,627, as well as U.S. Patents 8,372,826 and 6,936,599 and pending patents for MS and other autoimmune diseases covering the uses of its oral estriol candidate, Trimesta(TM).
Synthetic Biologics to Present at the 26th Annual ROTH Conference
PR Newswire - Wed Mar 05, 6:00AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 26th Annual ROTH Conference being held on March 9-12, 2014 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. Mr. Riley is scheduled to present on Tuesday, March 11, 2014 at 2:00 p.m. (Pacific Time).
Board member of Synthetic Biologics, Steve H Kanzer, resigns
M2 - Thu Feb 27, 5:27AM CST
US-based biotechnology company Synthetic Biologics Inc (NYSE MKT:SYN) reported on Wednesday the resignation of its founder & board member, Steve H Kanzer.
Synthetic Biologics' Board of Directors Accepts Resignation of Long-Standing Founder and Board Member
PR Newswire - Wed Feb 26, 4:01PM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that Founder, Board member and subsidiary CEO and President, Steve H. Kanzer, has resigned from the Company, effective immediately, to return his focus to his venture capital and investment banking firms on a full-time basis.
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Synthetic Biologics (SYN) Worth Watching: Stock Soars 19.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:46AM CST
Synthetic Biologics was a big mover last session, with shares surging nearly 20%.
Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity
PR Newswire - Thu Feb 13, 2:57PM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that in view of the unusual market activity in the Company's stock, the NYSE MKT (the "Exchange") has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity.
Synthetic Biologics Announces Rhonda Voskuhl, M.D., to Present Trimesta(TM) Phase II Multiple Sclerosis Clinical Trial Results at the 2014 AAN Annual Meeting
PR Newswire - Mon Feb 10, 6:00AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Rhonda Voskuhl, M.D., the lead investigator of the Phase II clinical trial evaluating the Company's oral estriol product candidate, Trimesta(TM), for the treatment of relapsing-remitting multiple sclerosis (MS), will present topline results at the American Academy of Neurology's (AAN) 66th Annual Meeting in Philadelphia. The abstract titled, A Combination Trial of Estriol Plus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis, will be presented as part of the AAN Emerging Science program during two sessions, as follows:
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Synthetic Biologics to Present at the 2014 BIO CEO & Investor Conference
PR Newswire - Tue Feb 04, 6:00AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 10, 2014, at 10:00 a.m. (ET) at the Waldorf Astoria (Duke of Windsor room) in New York.
Intrexon: Living Better Through Synthetic Biology?
at Investor's Business Daily - Tue Jan 28, 1:03PM CST
Analysts have dropped their profit estimates for synthetic biotechnology firm Intrexon, and investors seem to be taking it in stride. Intrexon (XON) stock has soared this year, mainly on investor hopes of better results to come later from royalties...
Synthetic Biologics (SYN) Slumps: Stock Tanks 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:38AM CST
Synthetic Biologics shares fell by over 11%. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future.
Synthetic Biologics Strengthens Clinical & Regulatory Team to Support Expanding Pipeline of Infectious Disease Programs
PR Newswire - Mon Jan 27, 6:00AM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Joseph Sliman, M.D., M.P.H., joined the team and will assume the role of Senior Vice President, Clinical & Regulatory Affairs, previously held by Carol Reed, M.D. In this position, Dr. Sliman will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the Company's regulatory initiatives. Dr. Sliman has more than 18 years of experience in clinical and public health research, including 10 years directing clinical projects and product development, in therapeutic areas such as infectious diseases and vaccines. Synthetic Biologics also announced that Dr. Reed will continue to contribute to the Company's team as a key clinical & regulatory advisor.
Synthetic Biology - Global Strategic Business Report - 2013: Profiles Players such as Sapphire Energy, Inc., Gingko Bioworks Inc and
M2 - Thu Jan 09, 6:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/mvqmvm/synthetic_biology#summary) has announced the addition of the "Synthetic Biology - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Synthetic Biology in US$ Thousands by the following Application Areas: - Energy & Chemicals - Biotechnology & Pharmaceuticals - Others The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 38 companies including many key and niche players such as: -454 Life Sciences (US) -Agilent Technologies Inc. (US) -ATG Biosynthetics GmbH (Germany) -BP PLC. (UK) -Chromatin Inc. (US) -DNA2.0 (US) -E. I. du Pont de Nemours and Company (US) -Epoch Life Science, Inc. (US -Evolva SA (Switzerland) -Gen9 Inc (US) -GenScript USA, Inc. (US) -Gevo, Inc. (US) -Gingko Bioworks Inc (US) -Intrexon Corporation (US) -Joule Unlimited, Inc. (US) -LC Sciences LLC (US) -Life Technologies Corp. (US) -LS9, Inc. (US) -Metabolix (US) -MorphoSys AG (Germany) -OPXBIO Inc. -OriGene Technologies, Inc. -Sangamo BioSciences, Inc. (US) -Sapphire Energy, Inc. (US) -Solazyme, Inc. (US) -Synthetic Biologics, Inc. (US) -Synthetic Genomics, Inc. (US) -Verdezyne, Inc. For more information visit http://www.researchandmarkets.com/research/mv...gy#summary About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Synthetic Biologics to Present at the Biotech Showcase(TM) 2014 Conference
PR Newswire - Wed Jan 08, 1:06PM CST
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the Biotech Showcase(TM) 2014 conference next week in San Francisco, as follows:
